Alnylam Pharmaceuticals Inc. (ALNY)
$302.93
$-0.72
(-0.24%)
As on 05-Jun-2026 13:41EDT
Market cap
$40,318 Mln
Revenue (TTM)
$4,287 Mln
P/E Ratio
75.7
P/B Ratio
36.7
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
0.9 %
-
ROCE
12.9 %
-
Industry P/E
--
-
EV/EBITDA
43.6
-
Debt to Equity
0.9
-
Book Value
$--
-
EPS
$4.2
-
Face value
--
-
Shares outstanding
133,512,573
10 Years Aggregate
CFO
$-3,580.08 Mln
EBITDA
$-5,459.67 Mln
Net Profit
$-6,481.57 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Alnylam Pharmaceuticals (ALNY)
| -23.8 | 1.7 | -7.4 | -0.8 | 16.1 | 15.8 | 15.7 |
|
BSE Sensex
| -12.3 | -3.9 | -6.2 | -8.3 | 5.9 | 7.3 | 10.7 |
|
S&P 100
| 5.5 | 2.6 | 8.6 | 24.9 | 22.1 | 13.7 | 14.7 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Alnylam Pharmaceuticals (ALNY)
| 69.0 | 22.7 | -19.5 | 40.1 | 30.5 | 12.9 | 58.0 |
|
S&P 100
| 18.7 | 29.0 | 30.8 | -22.1 | 27.6 | 19.3 | 29.5 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Alnylam Pharmaceuticals (ALNY)
|
302.9 | 40,318.1 | 4,286.9 | 577.2 | 9.8 | 88.2 | 75.7 | 36.7 |
| 94.4 | 23,173.0 | 819.6 | -1,183.8 | -141.4 | -143.4 | -- | 33.5 | |
| 74.5 | 12,642.6 | 1,057.9 | -326.6 | -16.4 | -58.9 | -- | 25.7 | |
| 184.2 | 30,617.8 | 16,632.0 | 1,385.0 | 14.1 | 22.3 | 22.8 | 5.0 | |
| 48.2 | 18,724.3 | 2,225.0 | -3,194.0 | -143.4 | -38.2 | -- | 2.6 | |
| 165.4 | 15,917.1 | 3,102.4 | 668.6 | 27.4 | 20.9 | 24.3 | 4.7 | |
| 636.6 | 64,452.9 | 14,919.6 | 4,423.4 | 34.9 | 14.2 | 15 | 2.1 | |
| 14.8 | 13,613.9 | 0.0 | -872.2 | -- | -287.7 | -- | 24.7 | |
| 546.5 | 23,635.2 | 3,169.8 | 1,287.4 | 51.4 | 20.6 | 20.6 | 4.0 | |
| 452.0 | 113,588.1 | 12,255.1 | 4,338.3 | 31.7 | 23.7 | 26.5 | 5.9 |
Shareholding Pattern
View DetailsAbout Alnylam Pharmaceuticals (ALNY)
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary... transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts. Read more
-
CEO & Director
Dr. Yvonne L. Greenstreet M.B.A., MBChB
-
CEO & Director
Dr. Yvonne L. Greenstreet M.B.A., MBChB
-
Headquarters
Cambridge, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Alnylam Pharmaceuticals (ALNY)
What is the current share price of Alnylam Pharmaceuticals Inc (ALNY) Today?
The share price of Alnylam Pharmaceuticals Inc (ALNY) is $302.93 (NASDAQ) as of 05-Jun-2026 13:41 EDT. Alnylam Pharmaceuticals Inc (ALNY) has given a return of 16.08% in the last 3 years.
What is the current PB & PE ratio of Alnylam Pharmaceuticals Inc (ALNY)?
The P/E ratio of Alnylam Pharmaceuticals Inc (ALNY) is 75.68 times as on 29-May-2026.
The P/B ratio of Alnylam Pharmaceuticals Inc (ALNY) is 36.70 times as on 29-May-2026, a 725 premium to its peers’ median range of 4.45 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
172.73
|
68.67
|
|
2024
|
-108.78
|
451.03
|
|
2023
|
-54.61
|
-108.97
|
|
2022
|
-25.90
|
-185.14
|
|
2021
|
-23.82
|
34.53
|
What is the 52 Week High and Low of Alnylam Pharmaceuticals Inc (ALNY)?
The 52-week high and low of Alnylam Pharmaceuticals Inc (ALNY) are Rs 495.55 and Rs 283.10 as of 07-Jun-2026.
What is the market cap of Alnylam Pharmaceuticals Inc (ALNY)?
Alnylam Pharmaceuticals Inc (ALNY) has a market capitalisation of $ 40,318 Mln as on 29-May-2026. As per SEBI classification, it is a Large Cap company.
Should I invest in Alnylam Pharmaceuticals Inc (ALNY)?
Before investing in Alnylam Pharmaceuticals Inc (ALNY), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.